Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 20211-20220 Newer>

The Motley Fool January 29, 2007 Tom Taulli	Callidus: Something Bullish Going On Reports of the enterprise software developer's death were greatly exaggerated. Going forward, Callidus pegs first-quarter revenues of $20.5 million to $22 million, which is up 21% to 29% from the year-ago numbers.
The Motley Fool January 29, 2007 Matthew Crews	Occidental Petroleum Slips While energy prices are wrecking most energy companies' fourth-quarter earnings, Oxy's strong cash flows, disciplined capital spending, and low balance sheet leverage should help stabilize it from any continued weakness in the energy market.
The Motley Fool January 29, 2007 Tom Taulli	NCR: Two Are Better Than One The spinoff of NCR's Teradata appears to be on track, but in the meantime, both divisions are performing quite nicely. Investors, take note.
The Motley Fool January 29, 2007 Tom Taulli	VistaPrint's Christmas Gift for Investors VistaPrint keeps growing at a hefty rate. So does the stock price.
The Motley Fool January 29, 2007 Will Frankenhoff	British American Tobacco Should Light Up Returns This is one defensive stock with some addictive returns. Investors should consider a position in the world's most geographically diverse tobacco company.
The Motley Fool January 29, 2007 Rich Smith	Foolish Forecast: Uncomfortable Furniture Brands The furniture company is set to release its fourth-quarter and full-year 2006 earnings results. Investors, here is what you can expect to see.
The Motley Fool January 29, 2007 Rich Duprey	Foolish Forecast: Kellogg's Looks Cracklin' Good The breakfast cereal maker will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool January 29, 2007 Jack Uldrich	IBM and Intel Install a New Gatekeeper Changes to transistor components will keep Moore's Law running smoothly. Which companies stand to come out on top? Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
<Older 20211-20220 Newer> Return to current articles.